A multi-component meningococcal serogroup B vaccine (4CMenB): The clinical development program

Drugs

Volumn 74, Issue 1, 2014, Pages 15-30

  O'Ryan, Miguel ^a   Stoddard, Jeffrey ^b   Toneatto, Daniela ^b   Wassil, James ^b   Dull, Peter M ^b  

^a UNIVERSITY OF CHILE   (Chile)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; 4CMENB VACCINE;

ANTIBODY RESPONSE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE CONVULSION; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; MALAISE; MENINGOCOCCOSIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEISSERIA MENINGITIDIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SERUM BACTERICIDAL ACTIVITY; VACCINATION; CLINICAL TRIAL (TOPIC); DRUG ADMINISTRATION; IMMUNOLOGY; MENINGOCOCCAL INFECTIONS;

CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES;

EID: 84893086355     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0155-7     Document Type: Review

References (39)

1. Racloz VN, Luiz SJ. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis. 2010;10:175-83.
2. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe (2007); 2012. http://www.ecdc.europa.eu/ en/publications/Publications/101011-SUR-Surveillance-of-invasive-bacterial- diseases-in-Europe-2007.pdf (Accessed 14 Aug 2012).
3. Centers for Disease Control and Prevention. Active bacterial core surveillance report, emerging infections program network, Neisseria meningitidis; 2008. http://www.cdc.gov/abcs/reports-findings/survreports/ mening08.html (Accessed 14 Aug 2012).
4. Bettinger JA, Deeks SL, Halperin SA, Tsang R, Scheifele DW. Controlling serogroup B invasive meningococcal disease: the Canadian perspective. Exp Rev Vacc. 2013;12:505-17.
5. Halperin SA, Bettinger JA, Greenwood B, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(Suppl 2):B26-36.
6. Sáfadi MAP, de los Monteros LE, López EL, et al. The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative. Exp Rev Vaccines. 2013;12:903-15.
7. Zollinger WD, Poolman JT, Maiden MC. Meningococcal serogroup B vaccines: will they live up to expectations? Expert Rev Vaccines. 2011;10:559-61.
8. Jolley KA, Brehony C, Maiden MC. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev. 2007;31:89-96.
9. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338:1093-6.
10. Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27(Suppl 2):B3-12.
11. O'Hallahan J, McNicholas A, Galloway Y, O'Leary E, Roseveare C. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. N Z Med J. 2009;122:48-59.
12. Hao W, Ma JH, Warren K, et al. Extensive genomic variation within clonal complexes of Neisseria meningitidis. Genome Biol Evol. 2011;3:1406-18.
13. Wassil J, McIntosh EDG, Serruto D, DeTora L, Broker M, Kimura A. The early clinical development of a multicomponent vaccine against meningococcal serogroup B. Clin Invest. 2012;2:503-17.
14. Mora M, Veggi D, Santini L, Pizza M, Rappuoli R. Reverse vaccinology. Drug Discov Today. 2003;8:459-64.
15. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA. 2006;103:10834-9.
16. Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis. 2010;50(Suppl 2):S54-65.
17. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009;27(suppl 2):B112-6.
18. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969;129:1327-48.
19. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307-26.
20. Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24:5093-107.
21. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51:1127-37.
22. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29:e71-9.
23. Toneatto D, Ismaili S, Ypma E, Vienken K, Oster P, Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin. 2011;7:646-53.
24. Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011;18:483-6.
25. Snape MD, Saroey P, John TM, et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ. 2013;185:E715-24.
26. Snape MD, Philip J, John TM, et al. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. PIDJ. 2013;32:1116-21.
27. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307:573-82.
28. Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381:825-35.
29. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379:617-24.
30. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vacc Immunother. 2013;9. doi: 10.4161/hv.25505.
31. Prymula R, Esposito S, Kittel C, et al. Prophylactic paracetamol in infants decreases fever following concomitant administration of an investigational meningococcal serogroup B vaccine with routine immunizations. 29th annual meeting of the European Society for Paediatric Infectious Diseases, The Hague; 2011.
32. Holst J, Oster P, Arnold R, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future. Hum Vacc Immunother. 2013;9:1-13.
33. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107:19490-5.
34. Vogel U, Taha MK, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13:416-25.
35. Frosi G, Biolchi A, Lo Sapio M, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31:4968-74.
36. Plikaytis BD, Stella M, Boccadifuoco G, et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol. 2012;19:1609-17.
37. Read RC, Baxter D, Chadwick DR, et al. Impact of a quadrivalent conjugate (MenACWY-CRM) or a serogroup B (4CMenB) meningococcal vaccine on meningococcal carriage in English university students. 31st meeting of the European Society for Paediatric Infectious Diseases, Milanl; 2013.
38. Caesar NM, Myers KA, Fan X. Neisseria meningitidis serogroup B vaccine development. Micro Pathogen. 2013;57:33-40.
39. Marshall HS, Richmond PC, Nissen MD, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine. 2013;12:1569-75.